Published in Obesity and Diabetes Week, August 9th, 2004
APD356 is an orally administered small molecule that is a selective 5-HT2C serotonin receptor agonist. The 5-HT2C receptor is located in an area of the brain believed to play an important role in regulating food intake and metabolism.
This first clinical study of APD356 explored the relationship among dose, concentration, and desired and undesired effects. Highlights of the study include:
1) Evidence of a pharmacologic effect on food intake was seen with a single 10 mg dose of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week